Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation

Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors

(2018) Alicja Puszkiel et al.   CLINICAL PHARMACOKINETICS

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

(2017) Murat Fani Bozkurt et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Long-Acting Somatostatin Analog Therapy Differentially Alters68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions

(2017) Narjess Ayati et al.   JOURNAL OF NUCLEAR MEDICINE

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

(2017) Bryan Oronsky et al.   NEOPLASIA

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

(2017) Arvind Dasari et al.   JAMA Oncology

Twins in spirit part II: DOTATATE and high-affinity DOTATATE—the clinical experience

(2014) Claudia Brogsitter et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature

(2014) Camilla Bardram Johnbeck et al.   Future Oncology

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis

(2013) Håkan Geijer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors

(2013) Amir Sabet et al.   EJNMMI Research

Current knowledge on diagnosis and staging of neuroendocrine tumors

(2011) Kjell Öberg et al.   CANCER AND METASTASIS REVIEWS

Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors

(2011) A. R. Haug et al.   JOURNAL OF NUCLEAR MEDICINE

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

(2010) Irene Virgolini et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2 - clinical implications

(2010) Mehtap Cakir et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

(2010) Irina Velikyan et al.   NUCLEAR MEDICINE AND BIOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY